Treating acne vulgaris: Systemic, local and combination therapy

Expert Review of Clinical Pharmacology

Volumn 3, Issue 4, 2010, Pages 563-580

  Savage, Laura J ^a   Layton, Alison M ^a  

^a HARROGATE DISTRICT HOSPITAL   (United Kingdom)

Author keywords

acne; acne surgery; antibiotic; benzyl peroxide; hormonal therapy; isotretinoin; light therapy; Proprionibacterium acnes; retinoid

Indexed keywords

ADAPALENE; AZELAIC ACID; AZITHROMYCIN; BENZAMYCIN; BENZOYL PEROXIDE; CEPHALOSPORIN DERIVATIVE; CHLORMADINONE ACETATE; CLINDAMYCIN; CYPROTERONE ACETATE; DIANE; DOXYCYCLINE; EPIDUO; ERYTHROMYCIN; ESTELLE 35; GLYCOLIC ACID; HYDROXYCHLOROQUINE; IMIDAZOLE; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; NICOTINAMIDE; OXYTETRACYCLINE; PLACEBO; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RETINOID; RETINOL; SALICYLIC ACID; SPIRONOLACTONE; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE CONGLOBATA; ACNE VULGARIS; AGRANULOCYTOSIS; ANDROGEN SYNTHESIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; AUTOIMMUNE HEPATITIS; AZOOSPERMIA; BACTERICIDAL ACTIVITY; BLEPHAROCONJUNCTIVITIS; BLOOD CLOTTING DISORDER; BRAIN PSEUDOTUMOR; BREAST TENDERNESS; CHEILITIS; CHLOASMA; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; COMEDO; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DERMATITIS; DIARRHEA; DIODE LASER; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; FACIAL DERMATITIS; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; INTRACRANIAL PRESSURE; IRRITANT DERMATITIS; LIBIDO; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MENSTRUAL IRREGULARITY; MINIMUM INHIBITORY CONCENTRATION; MOOD CHANGE; NAUSEA; NEPHROTOXICITY; NIGHT BLINDNESS; ONYCHOLYSIS; OUTCOME ASSESSMENT; PARONYCHIA; PATHOGENESIS; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PHOTOTHERAPY; PRACTICE GUIDELINE; PSEUDOMEMBRANOUS COLITIS; PULSED DYE LASER; PYOGENIC GRANULOMA; REVIEW; SIDE EFFECT; SKIN IRRITATION; SKIN PIGMENTATION; SUICIDAL IDEATION; TENDINITIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; URTICARIA; VESTIBULAR DISORDER; VESTIBULITIS; WEIGHT FLUCTUATION;

EID: 77954916940     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.27     Document Type: Review

References (198)

1. Cunliffe WJ, Gollnick H. Acne: Diagnosis and Management. Marks R (Ed.). Martin Dunitz Ltd., London, UK 121 (2001).
2. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch. Dermatol. 115, 571-575 (1979).
3. Pillsbury DM, Shelley WB, Kligman AM. A Manual of Cutaneous Medicine. Saunders, PA, USA 173 (1961).
4. Finlay AY, Khan GK. Dermatology life quality index (DLQI). A simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210-216 (1994).
5. Layton AM, Seukeran DC, Cunliffe WJ. Scarred for life. Dermatology 195, 15-21.
6. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin. Exp. Dermatol. 17, 1-3 (1992).
7. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc. Sci. Med. 20, 425-429 (1985).
8. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br. J. Dermatol. 139, 846-850 (1998).
9. Kellet SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br. J. Dermatol. 140, 273-282 (1999).
10. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch. Dermatol. 134, 454-458 (1998) .
11. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br. J. Dermatol. 137(2), 246-250 (1997).
12. Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. Cutis 81(1), 81-86 (2008).
13. Gollnick H, Cunliffe W, Berson D et al. Global Alliance to improve outcomes in acne. Management of acne: a report from a Global Alliance to improve outcomes in acne. J. Am. Acad. Dermatol. 49(1), S1-S37 (2003).
14. Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J. Am. Acad. Dermatol. 60(5), S1-S50 (2009).
15. Layton AM. Disorders of the sebaceous glands. In: Rook's Textbook of Dermatology (8th Edition). Burns DA, Breathnach SM, Cox NH et al (Eds). Blackwell Publishing, London, UK (2010).
16. Dreno B, Bettoli V, Ochsendorf F et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur. J. Dermatol. 15, 565-571 (2006).
17. Caron D, Sorba V, Kerrouche N et al. A split-face comparison of adapalene 0.1% gel and tretinoin gel 0.025% gel in acne patients. J. Am. Acad. Dermatol. 36, S110-S112 (1997). (Pubitemid 27265890)
18. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicentre trial. J. Am. Acad. Dermatol. 34, 482-485 (1996).
19. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomised open-label clinical trial. Br. J. Dermatol. 147, 523-527 (2002).
20. Christophers E, Wolfe HH. Effect of vitamin A acid on skin: in vivo and in vitro studies. Acta Derm. Venereol. 74, 42-53 (1975).
21. Leyden JJ. Rational therapy for acne vulgaris: an update on topical treatment. J. Am. Acad. Dermatol. 15, 907-915 (1986).
22. Bouclier M, Chatelus A, Ferracin J et al. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol. 4, 65-73 (1991).
23. Cunliffe WJ, Poncet M, Loesche C et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris. A meta-analysis of five randomised trials. Br. J. Dermatol. 139(Suppl. 52), 48-56 (1998).
24. Schefer H. Penetration and percutaneous absorption of topical retinoids. A review. Skin Pharmacol. 6, 17-23 (1993).
25. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzyl peroxide: effects on the surface and follicular cutaneous microflora. Br. J. Dermatol. 132, 204-208 (1995).
26. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 292, 726-735 (2004).
27. Fulton JE, Farzad-Batshandeth A. Studies on the mechanism of action of topical benzyl peroxide in acne vulgaris. J. Cutan. Pathol. 1, 194-200 (1974).
28. Goldstein JA, Pochi PE. Failure of benzoyl peroxide to decrease sebaceous gland secretion in acne. Dermatologica 162, 287-291 (1981).
29. Tucker SB, Tausend R, Cochran R et al. Comparison of topical clindamycin phosphate, benzyl peroxide and a combination of the two for treatment in acne vulgaris. Br. J. Dermatol. 110, 487-492 (1984).
30. Swinyer LJS, Barker MD, Swinyer TA et al. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br. J. Dermatol. 119, 615-622 (1998).
31. Lookingbill DP, Chalker DK, Lind Holm JS et al. Treatment of acne with a combination clindamycin/benzoyl peroxide and vehicle gel; combined with results of two double blind investigations. J. Am. Acad. Dermatol. 37, 590-595 (1997).
32. Ozolins M, Eady EA, Avery A et al. A cost-effectiveness rationale for the selection of anti-microbial therapy in acne: a randomized controlled trial. Br. J. Dermatol. 147, 13-18 (2002).
33. Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. Int. J. Dermatol. 18, 489-496 (1979).
34. Mills OH, Kligman AM, Pochi P et al. Comparing 2.5%, 5% and 10% benzoyl peroxide on inflammatory acne vulgaris. Int. J. Dermatol. 25, 664-667 (1986).
35. Yong CC. Benzoyl peroxide gel therapy in acne in Singapore. Int. J. Dermatol. 18, 485-488 (1979).
36. Marsden J. Evidence that the method of use, dose and duration of treatment with benzoyl peroxide and tetracycline determines response of acne. J. R. Soc. Med. 78 (Suppl. 10), 25-28 (1985).
37. Thiboutot DM, Weis J, Bucko A et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J. Am. Acad. Dermatol. 57, 791-799 (2007).
38. Cunliffe WJ. The clinical efficacy of azelaic acid in the treatment of acne. Rev. Contemp. Pharmacother. 4, 433-439 (1993).
39. Cunliffe WJ. Azelaic acid - review of its role in acne. J. Dermatol. Treat. 4(Suppl. 1), S12-S18 (1993).
40. Silva A, Gollnick H, Detmar M et al. Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinisation pattern in human skin. Acta Derm. Venereol. 143, 20-30 (1989).
41. Kurokawa I, Akamatsu H, Nishijima S et al. Clinical and bacteriologic evaluation of OP-7251 in patients with acne; a double-blind group comparison study versus cream base. J. Am. Acad. Dermatol. 25, 674-681 (1991).
42. Holland KT, Bojar RA. Antimicrobial effects of azelaic acid. J. Dermatol. Treat. 4, S8-S11 (1993).
43. Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br. J. Dermatol. 15, 551-556 (1986).
44. Bernstein JE, Shalita AR. Effects of topical erythromycin on aerobic and anaerobic surface flora. Acta Derm. Venereol. 60, 537-538 (1980).
45. Basak PY, Gultekin F, Kilinc I et al. The effect of benzoyl peroxide and benzoyl peroxide/erythromycin combination on the anti-oxidative defence system in papulo pustular acne. Eur. J. Dermatol. 12, 53-57 (2002).
46. Leyden JJ. Therapy for acne vulgaris. N. Engl. J. Med. 336, 1156-1162 (1997).
47. Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc; effect of Propionibacterium acnes and free fatty acid composition. J. Am. Acad. Dermatol. 11, 86-89 (1984).
48. Henderson TA, Olson WH, Leach AD. A single blind, randomised comparison of erythromycin pledgets and clindamycin lotion in the treatment of mild to moderate facial acne vulgaris. Adv. Ther. 12, 172-177 (1995).
49. Leyden JJ, Shalita AR, Saatjian GD et al. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J. Am. Acad. Dermatol. 16, 822-827 (1987).
50. Padilla RS, McCabe JM, Becker LE. Topical tetracycline hydrochloride vs topical clindamycin phosphate in the treatment of acne; a comparative study. Int. J. Dermatol. 20, 445-448 (1981).
51. Robledo AA, Lopez BE, del Pino GJ et al. Multicentric comparative study of the efficacy and tolerance of clindamycin phosphate 1% topical solution and tetracycline topical solution for the treatment of acne vulgaris. Curr. Ther. Res. Clin. Exp. 43, 23-26 (1988).
52. Eady EA, Cope JH, Jones DN et al. Topical antibiotics for the treatment of acne: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J. Dermatol. Treat. 1, 215-226 (1990).
53. Verschoore M, Langner A, Wolska H et al. Efficacy and safety of CD271 alcoholic gels in the topical treatment of acne vulgaris. Br. J. Dermatol. 124, 368-371 (1991).
54. Bernstein JE, Lorincz AL. The effects of topical nicotinamide, tetracycline and dapsone and potassium-iodide induced inflammation. J. Invest. Dermatol. 74, 257-258 (1988).
55. Thiboutot D. Acne: an overview of clinical research findings. Dermatol. Clin. 15, 97-109 (1997).
56. Cunliffe WJ, Foster RA, Greenwood ND et al. Tetracycline and acne vulgaris: a clinical and laboratory investigation. BMJ 4(5888), 332-335 (1973).
57. Hassing GS. Inhibition of Corynebacterium acnes lipase by tetracycline. J. Invest. Dermatol. 56, 189-192 (1971).
58. Webster GP, Leyden JJ, McGinley KJ et al. Suppression of polymorphonuclear leukocyte chemotactic factor in Propionibacterium acnes by subminimal inhibitory concentrations of tetracyclines, ampicillin, minocycline and erythromycin. Antimicrob. Agents Chemother. 21, 770-777 (1982).
59. Akamatsu H, Asada M, Komura J et al. Effect of doxycycline on the generation of reactive oxygen species; a possible mechanism of action of acne therapy with doxycycline. Acta Derm. Venereol. 72, 178-179 (1992).
60. Eady EA, Ingham E, Walters CE et al. Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines. J. Invest. Dermatol. 101, 86-91 (1993).
61. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes: microbiological and clinical aspects. Anaerobe 12, 207-210 (2006).
62. Raum E, Lietzau S, von Baum H et al. Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. Clin. Microbiol. Infect. 14, 41-48 (2008).
63. Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 364, 2188-2195 (2004).
64. Ross JL, Snelling AM, Carnegie E et al. Antibiotic resistant acne: lessons from Europe. Br. J. Dermatol. 148, 467-478 (2003).
65. Dreno B, Bettoli V, Ochsendorf F et al. European recommendations on the use of oral antibiotics for acne. Eur. J. Dermatol. 14, 391-399 (2004).
66. Thiboutot D. New treatments and therapeutic strategies for acne. Acad. Fam. Med. 9, 179-187 (2000).
67. Cunliffe WJ, Clayden AD, Gould D et al. Acne vulgaris - its aetiology and treatment. A review. Clin. Exp. Dermatol. 6, 461-469 (1981).
68. Gibson JR, Darley CR, Harvey SG et al. Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris. Br. J. Dermatol. 107, 221-224 (1982).
69. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology 187, 193-196 (1993).
70. Cunliffe WJ, Aldana OL, Goulden V et al. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br. J. Dermatol. 141, 757-758 (1999).
71. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim in the treatment in the treatment of acne vulgaris. Cutis 79, 430-434 (2007).
72. Amin K, Riddle CC, Aires DJ et al. Common and alternative oral therapies for acne vulgaris: a review. J. Drugs Dermatol. 6, 873-880 (2007).
73. Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J. Drugs Dermatol. 17, 217-221 (2006).
74. Carraso DA, Vander Straten M, Tyring SK. A review of antibiotics in dermatology. J. Cut. Med. Surg. 6, 128-150 (2002).
75. Knagga HE, Layton AM, Cunliffe WJ. The role of oral minocycline and erythromycin in tetracycline therapy- resistant acne - a retrospective study and review. J. Dermatol. Treat. 4, 53-56 (1993).
76. Greenwood R, Burke B, Cunliffe WJ. Evaluation of a therapeutic strategy for the treatment of acne vulgaris with conventional therapy. Br. J. Dermatol. 114, 353-358 (1986).
77. Coates P, Adams CA, Cunliffe WJ et al. Does oral isotretinoin prevent propionibacteria acnes resistance? Dermatology 195(Suppl. 1), 4-9 (1997).
78. De Rossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent. Clin. North Am. 46(4), 653-654 (2002).
79. Layton AM. A review on the treatment of acne vulgaris. Int. J. Clin. Pract. 60(1), 64-72 (2006).
80. Leyden JJ. New understandings of the pathogenesis of acne. J. Am. Acad. Dermatol. 32(Suppl.), 15-25 (1995).
81. Cunliffe WJ. Acne, hormones and treatment. BMJ (Clin. Res. Ed.) 285(6346), 912-913 (1982).
82. Stewart ME, Downing DT, Cook JS et al. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch. Dermatol. 128, 1345-1348 (1992).
83. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 81, 70-74 (1998).
84. Lucky AW, McGuire J, Rosenfield RL et al. Plasma androgens in women with acne vulgaris. J. Invest. Dermatol. 81, 70-74 (1983).
85. Vexlau P, Husson C, Chivot M et al. Androgen excess in women with acne alone compared with acne and/or hirsutism. J. Invest. Dermatol. 94, 279-283 (1990).
86. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation and therapies. Sem. Cutan. Med. and Surg. 20, 144-153 (2001).
87. Darley CR, Moore JW, Besser GM et al. Low dose prednisolone or oestrogen in the treatment of women with late onset or persistent acne vulgaris. Br. J. Dermatol. 108, 345-353 (1983).
88. Lucky A. Hormonal correlates of acne and hirsutism. Am. J. Med. 98, 895-945 (1995).
89. Saihan E, Burton J. Sebaceous gland suppression in female acne patients by combined glucocorticoid-oestrogen treatment. Br. J. Dermatol. 103, 139-142 (1981).
90. Pochi P, Strauss J. Sebaceous gland inhibition from combined glucocorticoid- estrogen treatment. Arch. Dermatol. 112, 1108-1109 (1976).
91. Arowojolu AO, Gallo MF, Lopez LM et al. Combined oral contraceptive pills for the treatment of acne. Cochrane Database Syst. Rev. (1), CD004425 (2007).
92. Speroff L, De Cherney A. Evaluation of a new generation of oral contraceptives. Obstet. Gynecol. 81, 1034-1047 (1993).
93. van Vloten W, van Haselen CW, van Zuuren EJ. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69, 1-15 (2002).
94. Feucht CL, Allen BS, Chalker DS et al. Topical erythromycin with zinc in acne. A double-blind controlled study. J. Am. Acad. Dermatol. 3, 483-491 (1980).
95. Bojar RA, Eady EA, Jones CE et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br. J. Dermatol. 18, 410-413 (1994).
96. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzyl peroxide 5% vs three different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in-vivo comparative study. Am. J. Clin. Dermatol. 2, 263-266 (2001).
97. Habbema L, Koopmans B, Menke HE et al. A 4% erythromycin and zinc combination (Zineryt® ) versus 2% erythromycin (Eryderm® ) in acne vulgaris: a randomised, double-blind comparative study. Br. J. Dermatol. 121, 497-502 (1989).
98. Schactner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J. Am. Acad. Dermatol. 22, 252-260 (1990).
99. Mills O Jr, Thornsberry C, Cardin CW et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm. Venereol. 82, 260-265 (2002).
100. Eady EA, Cove JH, Holland KT et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br. J. Dermatol. 121, 51-57 (1989).
101. Leyden JJ, McGinley KJ, Cavalieri S et al. Propionibacterium acnes resistance to antibiotics in acne patients. J. Am. Acad. Dermatol. 8, 41-45 (1983).
102. Eady EA, Ingham E, Walters CE et al. Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines. J. Invest. Dermatol. 101, 86-91 (1993).
103. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne vulgaris. J. Dermatol. Treat. 6(Suppl. 1), 8-10 (1995).
104. Shalita AR, Smith JG, Parish LC et al. A double-blind comparison of topical nicotinamide with clindamycin gel for the treatment of inflammatory acne vulgaris. Int. J. Dermatol. 34, 34-37 (1995).
105. Faloia E, Filipponi S, Mancini V et al. Treatment with a gonadotrophin-releasing hormone agonist in acne or idiopathic hirsutism. J. Endocrinol. Invest. 16, 675-677 (1993).
106. Greenwood R, Burke B, Brummitt L et al. Cyclic cyproterone/ ethinyloestradiol for acne. Lancet 2(8353), 796 (1983).
107. Hanstead B, Reymann F. Cyproterone acetate in the treatment of acne vulgaris in adult females. Dermatologica 164, 117-126 (1982).
108. Miller JA, Wojnarowska FT, Dowd PM et al. Anti-androgen treatment in women with acne: a controlled trial. Br. J. Dermatol. 114, 705-716 (1986).
109. Vasiakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone contraceptives. Lancet 358, 1427-1429 (2001).
110. Franks S, Layton A, Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum. Repod. 23, 231-232 (2008).
111. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339, B2921 (2009).
112. Thiboutot DM, Knaggs H, Gilliland K et al. Activity of type 1 5a-reductase is greater in the follicular infundibulum compared with the epidermis. Br. J. Dermatol. 136, 166-171 (1997).
113. Greenwood R, Brummitt L, Burne B et al. Acne: double-blind clinical and laboratory trial of tetracycline, oestrogen, cyproterone acetate and combined treatment. BMJ 291, 1231-1235 (1985).
114. van Wayjen R, van den Ende A. Experience in the long-term treatment of patient with hirsutism and/or acne with cyproterone acetate containing preparations: efficacy, metabolic and endocrine effects. Exp. Clin. Endocrinol. Diabetes 103, 241-251 (1995).
115. Gollnick H, Albring M, Brill K. Effcacite de l'acetate de cyproterone oral associe a l'ethinylestradiol dans le traitement de l'acne tardive de type facial. Ann. Endocrinol. 60, 157-166 (1999).
116. Sawaya ME, Hordinsky MK. The antiandrogens: when and how they should be used. Dermatol. Clin. 11, 65-72 (1993).
117. Muhlemann MF, Carter GD, Cream JJ et al. Oral spironalactone: an effective treatment for acne vulgaris in women. Br. J. Dermatol. 115, 227-232 (1986).
118. Goodfellow A, Alaghband-Zadeh J, Carter C et al. Oral spironalactone improves acne vulgaris and reduces sebum excretion. Br. J. Dermatol. 111, 209-214 (1984).
119. Lubbos H, Rose LI. Adverse effects of spironalactone therapy in women with acne. Arch. Dermatol. 134, 1162-1163 (1998).
120. Thiboutot D. Acne: hormonal concepts and therapy. Clin. Dermatol. 22, 419-428 (2004).
121. Farquhar C, Lee O, Toomath R et al. Spironalactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst. Rev. (4), CD000194 (2003).
122. Shaw JC. Low dose adjunctive spironalactone in the treatment of acne in a retrospective analysis of 85 patients consecutively treated patients. J. Am. Acad. Dermatol. 43, 498-502 (2000).
123. Marcoux D, Thiboutot D. Hormonal therapy for acne. J. Cutan. Med. Surg. 1(Suppl. 1), 52-56 (1996).
124. Loube SD, Quirk RA. Breast cancer associated with administration of spironalactone. Lancet 1(7922), 1428-1429 (1975).
125. Calaf J, Lopez E, Millet A et al. Long term efficacy and tolerability of flutamide compared with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J. Clin. Endocrinol. Metab. 92, 3446-3450 (2007).
126. Cusan L, Dupont A, Gomez FL et al. Comparison of flutamide and spironalactone in the treatment of hirsutism: a randomized control trial. Fertil. Steril. 61, 281-287 (1995).
127. Wysowski D, Freiman J, Tourtelot J et al. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118, 860-864 (1993).
128. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J. Urol. 155, 209-212 (1996).
129. Martin KA, Chang RJ, Ehrmann DA et al. Evaluation and treatment of hirsutism in pre-menopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1105-1120 (2008).
130. Moghetti P, Castello R, Negri C et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behaviour. Fertil. Steril. 68, 644-647 (1995).
131. Castelo-Branco C, Moyano D, Gomez O et al. Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil. Steril. 91(4), 1183-1188 (2009).
132. de Zegher F, Ibanez L. Low dose flutamide for women with androgen excess: anti-androgenic efficacy and hepatic safety. J. Endocrinol. Invest. 32, 83-84 (2009).
133. Calaf J, Lopez E, Millet A et al.; the Spanish Working Group for Hirsutism. Long term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism. A 12-month, double-blind parallel clinical trial. J. Clin. Endocrinol. Metab. 92, 3446-3452 (2007).
134. King K, Jones DH, Daltry DC et al. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br. J. Dermatol. 107, 583-590 (1982).
135. Allenby G, Bocquel MT, Saunders M et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc. Natl Acad. Sci. USA 90, 30-34 (1993).
136. Tsukada M, Schroder M, Roos TC et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerisation to all-trans-retinoic acid and binding to retinoid acid receptors. J. Invest. Dermatol. 115, 321-327 (2000).
137. Layton AM, Knaggs HE, Taylor J et al. Isotretinoin for acne vulgaris - 10 years later. A safe and successful treatment. Br. J. Dermatol. 129, 292-296 (1993).
138. Ward A, Brogden RN, Heel RC et al. Isotretinoin: a review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 28, 6-37 (1984). (Pubitemid 14112379)
139. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoin acid: evaluation of sebum production and the clinical response in a multiple dose trial. J. Am. Acad. Dermatol. 3, 602-611 (1980).
140. Dalziel K, Barton S, Marks R. The effect of isotretinoin on follicular and sebaceous gland differentiation. Br. J. Dermatol. 117, 317-323 (1987).
141. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J. Invest. Dermatol. 86, 390-393 (1986).
142. Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. J. Am. Acad. Dermatol. 6, 751-755 (1982).
143. Layton AM, Dreno B, Gollnick HPM et al. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 20, 773-776 (2006).
144. Colburn WA, Gibson DM, Wiens RE et al. Food increases the bioavailability of isotretinoin. J. Clin. Pharmacol. 23, 534-538 (1983).
145. Soria C, Allegue F, Galiana J et al. Decreased isotretinoin efficacy during acute alcohol intake. Dermatologica 182, 203 (1991).
146. Harms M, Masye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age related: a long term follow up study. Dermatologica 172, 148-153 (1986).
147. Goulden V, Clark M, McGeown C et al. Treatment of acne with intermittent isotretinoin. Br. J. Dermatol. 137, 106-108
148. Akman A, Durusoy C, Senturk M et al. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicentre study. Arch. Dermatol. Res. 299, 467-473 (2007).
149. Clark SM, Goulden V, Cunliffe WJ. The management of acne patients who respond slowly to oral isotretinoin. Br. J. Dermatol. 135-1120 (1996).
150. Lehucher-Ceyrac D, Salmoniere P, Chastang C et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 198, 278-283 (1999).
151. Stainforth JM, Layton AM, Taylor JP et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br. J. Dermatol. 129, 297-301 (1993).
152. White GM, Yao J, Wolde-Tsadik G. Recurrence rates after one course of isotretinoin. Arch. Dermatol. 134, 376-378
153. Clark SM, Cunliffe WJ. Acne flare and isotretinoin - incidence and treatment. Br. J. Dermatol. 133(Suppl. 45), 26 (1995).
154. Pepall LM, Cosgrove MP, Cunliffe WJ. Ablation of whiteheads by cautery under topical anaesthetic. Br. J. Dermatol. 125, 256-259 (1991).
155. Mitchell AA, van Bennekom CM, Louik C. A pregnancy prevention program in women of child-bearing age receiving isotretinoin. N. Engl. J. Med. 333, 101-106 (1995).
156. Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin. N. Engl. J. Med. 320, 1007-1009 (1989).
157. Williams RE, Doherty VR, Perkins W et al. Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne. Br. J. Dermatol. 126, 362-366
158. Karvone S. Acne fulminans: report of clinical findings and treatment of 24 patients. J. Am. Acad. Dermatol. 28, 572-579 (1993).
159. Jick S, Kremers H, Vasilakis- Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide and attempted suicide. Arch. Dermatol. 136, 1231-1236 (2000).
160. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression and isotretinoin: is there a causal risk? J. Am. Acad. Dermatol. 45, S168-S175 (2001).
161. Wysowaski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J. Am. Acad. Dermatol. 45, S15-S19 (2001).
162. Azoulay L, Blais L, Koren G et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case cross over study. J. Clin. Psych. 198, E1-E7 (2008).
163. Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 55, 165-168 (1995).
164. Amichai B, Grunwald MH. Isotretinoin in dermatology. J. Dermatol. Treat. 11, 219-240 (2000).
165. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 204, 232-235 (2002).
166. Bottomley WW, Yip J, Knaggs H et al. Treatment of closed comedones - comparisons of fulguration with topical tretinoin and electrocautery with fulguration. Dermatology 186, 253-257 (1999).
167. Horton CE, Sadove RC. Refinements in combined chemical peel and simultaneous abrasion of the face. Ann. Plast. Surg. 19, 504-511 (1987).
168. Monheit GD. The Jessner's tricholoroacetic acid peel. An enhanced medium depth chemical peel. Dermatol. Clin. 13, 273-283 (1995).
169. Furukawa F, Yamamoto Y. Recent advances in chemical peeling in Japan. J. Dermatol. 33, 655-661 (2006).
170. Orentreich N, Durr NP, Frank SB (Eds). Acne. Yorke Medical Books, NY, USA (1979).
171. Callen JP. Intralesional corticosteroids. J. Am. Acad. Dermatol. 4, 149-151 (1981).
172. Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch. Dermatol. 119, 480-481 (1983).
173. Schonberg IL, Litz JZ. Fluro-therapy cryotherapy: an adjuvant in the treatment of acne vulgaris and post acne scarring. Ohio Med. 54, 1046 (1958).
174. Elman M, Lebzelter J. Light therapy in the treatment of acne vulgaris. Dermatol. Surg. 30, 139-146 (2004).
175. Zeina B, Greenman J, Corry D et al. Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes. Br. J. Dermatol. 146, 568-573 (2002).
176. Ross EV. Optical treatments for acne. Dermatol. Ther. 18, 253-266 (2005).
177. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin. Dermatol. 24, 16-25 (2006).
178. Webster GF. Laser treatment of acne. Lancet 362, 1342 (2003).
179. Lloyd JR. Selective photothermolysis of the sebaceous glands for acne treatment. Lasers Surg. Med. 31, 115-120 (2002).
180. Mariwalla K. Use of lasers and light-based therapies for treatment of acne vulgaris. Lasers Surg. Med. 37(5), 333-342 (2005).
181. Hdersdal M, Togsverd-Bo K, Wulf HC. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 22, 267-278 (2008).
182. Horfelt C, Funk J, Frohm-Nilsson M et al. Topical methyl aminolevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br. J. Dermatol. 155, 608-613 (2006).
183. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolevulinate: a blinded, randomized, controlled trial. Br. J. Dermatol. 154, 969-976 (2006).
184. Wiegell SR, Wulf HC. Photodynamic therapy for acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J. Am. Acad. Dermatol. 54, 647-651 (2006).
185. Pollock B, Turner D, Stringer MR et al. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br. J. Dermatol. 151, 616-622 (2004).
186. Hongcharu W, Taylor CR, Chang Y et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J. Invest. Dermatol. 115, 183-192 (2000).
187. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinic acid: a blinded, randomized, controlled trial. Br. J. Dermatol. 154, 969-976 (2006).
188. Yeung CK, Shek SY, Bjerring P et al. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg. Med. 39, 1-6 (2007).
189. Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol. Surg. 32, 991-997 (2006).
190. Santos MA, Belo VG, Santos G. Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol. Surg. 31, 910-914 (2005).
191. Seaton ED, Charakida A, Mouser PE et al. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomized controlled trial. Lancet 362, 1347-1352 (2003).
192. Paithankar DY, Ross EV, Saleh BA et al. Acne treatment with a 1450 nm wavelength laser and cryogen spray cooling. Lasers Surg. Med. 31, 106-114 (2002).
193. Baugh WP, Kucaba WD. Nonablative phototherapy for acne vulgaris using the KTP 532 nm laser. Dermatol. Surg. 31, 1290-1295 (2005).
194. Gold MH, Rao J, Goldman MP et al. A multicentre clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J. Drugs Dermatol. 4, 64-70 (2005).
195. Tzung T-Y, Wu K-H, Huang M-L. Blue light phototherapy in the treatment of acne. Photodermatol. Photoimmunol. Photomed. 20, 266-269 (2004).
196. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br. J. Dermatol. 142, 973-978 (2000).
197. Car J, Car M, Hamilton F et al. The Cochrane Collaboration: Light Therapies for Acne (Protocol). The Cochrane Library (Issue 3). John Wiley and Sons Ltd, London, UK (2009).
198. iPLEDGE www.ipledgeprogram.com